Newcastle University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Newcastle University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014004
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Newcastle University (NU) is an educational university that offers teaching and research services. The university provides teaching and study services including postgraduate study, undergraduate study, and campus services. It offers teaching services in areas of accounting and finance; agri-business management, agriculture, ancient history, animal science, archaeology, biology and zoology. NU also provides services in business management, chemical engineering, civil engineering, classics and ancient history; computing science, history, journalism, law and others. The university offers research programs in humanities and social sciences; medical sciences, science, agriculture and engineering areas. It also provides accommodation to its students. The university has its operations in Malaysia, Singapore and the UK. NU is headquartered in Newcastle Upon Tyne, the UK.

Newcastle University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Newcastle University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Newcastle University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Newcastle University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Newcastle University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Newcastle University, Medical Devices Deals, 2011 to YTD 2017 9
Newcastle University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Newcastle University, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
QuantuMDx Raises USD8.4 Million in Venture Financing 11
Partnerships 12
DNA2.0 Enters Into Research Agreement With Newcastle University For Bacillus subtillis Expression System 12
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 13
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 15
Licensing Agreements 17
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 17
Newcells Biotech Receives IP Technology Rights from Newcastle University 18
Newcastle University – Key Competitors 19
Newcastle University – Key Employees 20
Newcastle University – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Government and Public Interest 22
Sep 14, 2017: Newcastle researchers awarded £1.7million to investigate heart attack treatments for patients over 75 22
Jul 20, 2017: £2 Million NIHR Award for Newcastle University to Focus on Dementia Care and Prevention on a Global Scale 24
Jun 08, 2016: New safety and efficacy evidence for mitochondrial donation revealed 25
May 19, 2016: New SHIELD to tackle antibiotic resistance 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Newcastle University, Pharmaceuticals & Healthcare, Key Facts 2
Newcastle University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Newcastle University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Newcastle University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Newcastle University, Deals By Therapy Area, 2011 to YTD 2017 8
Newcastle University, Medical Devices Deals, 2011 to YTD 2017 9
Newcastle University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
QuantuMDx Raises USD8.4 Million in Venture Financing 11
DNA2.0 Enters Into Research Agreement With Newcastle University For Bacillus subtillis Expression System 12
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 13
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 15
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 17
Newcells Biotech Receives IP Technology Rights from Newcastle University 18
Newcastle University, Key Competitors 19
Newcastle University, Key Employees 20
Newcastle University, Subsidiaries 21

★海外企業調査レポート[Newcastle University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • New Gold Inc.:企業のM&A・事業提携・投資動向
    New Gold Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Gold Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Merit Energy Company:石油・ガス:M&Aディール及び事業提携情報
    Summary Merit Energy Company (Merit Energy) is a financial service provider that offers oilfield investment services. The company provides direct investments in oil and gas assets. It purchases properties with a high percentage of producing reserves, implements exploitation projects to increase prod …
  • Pacific Biosciences of California Inc (PACB):製薬・医療:M&Aディール及び事業提携情報
    Summary Pacific Biosciences of California Inc (Pacific Biosciences) designs, develops, and manufactures sequencing instruments for solving complex genetic abnormalities. The company’s product portfolio comprises proprietary Phospholinked nucleotides, sequencing systems, analytical software and consu …
  • Hindustan Petroleum Corp Ltd (HINDPETRO):石油・ガス:M&Aディール及び事業提携情報
    Summary Hindustan Petroleum Corp Ltd (HPCL) is a downstream oil and gas company that carries out refining, transportation and marketing of petroleum products. It is also has operations in upstream segment of oil and gas industry. HPCL carries out exploration and production in India; and Australia. T …
  • Pharnext SA (ALPHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases. The company offers pleotherapy, a proprietary research and development platform based on network pharmacology that uses wide genomic data to ident …
  • Sernova Corp (SVA):企業の製品パイプライン分析2018
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like …
  • Swissquote Group Holding Ltd (SQN):企業の財務・戦略的SWOT分析
    Swissquote Group Holding Ltd (SQN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • National Fuel Gas Co (NFG):企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • PrairieSky Royalty Ltd (PSK):石油・ガス:M&Aディール及び事業提携情報
    Summary PrairieSky Royalty Ltd (PrairieSky Royalty) is an oil and gas company. The company carries out acquisition of fee simple lands from Encana Corporation and concurrent initial public offering. It also acquires and manages royalty lands, to generate free cash flow through indirect third-party o …
  • Charkit Chemical Company LLC:企業の戦略・SWOT・財務情報
    Charkit Chemical Company LLC - Strategy, SWOT and Corporate Finance Report Summary Charkit Chemical Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Thales Deutschland GmbH:企業の戦略・SWOT・財務情報
    Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report Summary Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Spero Therapeutics Inc (SPRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 …
  • Momenta Pharmaceuticals Inc (MNTA):企業の財務・戦略的SWOT分析
    Momenta Pharmaceuticals Inc (MNTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • DAIS Corp (DLYT):企業の財務・戦略的SWOT分析
    Summary Dais Corps (Dais) is an alternative energy company. It provides industry changing and nano technology based applications. The company's products include ultra capacitors, clean water systems, heating and cooling equipment, among others. It also provides NanoAir, NanoCap, ConsERV and NanoClea …
  • China Banking Corporation:企業の戦略・SWOT・財務情報
    China Banking Corporation - Strategy, SWOT and Corporate Finance Report Summary China Banking Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • GREE, Inc. (3632):企業の財務・戦略的SWOT分析
    GREE, Inc. (3632) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nuformix Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Nuformix Ltd (Nuformix) is a provider of pharmaceutical cocrystallisation products. The company develops and manufactures products in reprofiling, supergenerics and emerging markets areas. It offers methodologies for rational solid form discovery; and provides technologies for rapid solid fo …
  • Prosetta Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Prosetta Biosciences Inc (Prosetta Biosciences), formerly Prosetta Antiviral Inc is a developer of novel small-molecule antiviral drugs based on research on the cell-free protein synthesizing systems. The company uses cell-free protein synthesizing systems to identify new protein-protein int …
  • Asahi Group Holdings Ltd:企業のM&A・事業提携・投資動向
    Asahi Group Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Asahi Group Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Carlsberg A/S:企業の戦略・SWOT・財務情報
    Carlsberg A/S - Strategy, SWOT and Corporate Finance Report Summary Carlsberg A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆